Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of digital therapeutic sinCephalea for personalised nutrition versus control for migraine prevention: A 12-week open-label randomised clinical trial.

Cephalalgia : an international journal of headache·2026
Same author

Brain activity during acquisition of long visuospatial sequences.

Frontiers in cognition·2026
Same author

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Cephalalgia : an international journal of headache·2026
Same author

Weekend headache in migraine - fact or fiction? An observational study from DMKG-app data.

Cephalalgia : an international journal of headache·2026
Same author

Efficacy, IHS Guideline Adherence, and Methodological Quality of Noninvasive Neuromodulation Clinical Trials in Migraine and Cluster Headache: A Systematic Review.

European journal of neurology·2026
Same author

A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US.

Cephalalgia : an international journal of headache·2026

Related Experiment Video

Updated: Sep 19, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.3K

Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial.

Jasper Mecklenburg1, Charly Gaul2, Mira Fitzek1,3

  • 1Department of Neurology, Charité Universitätsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany.

JAMA Network Open
|June 17, 2025
PubMed
Summary

Erenumab, a CGRP receptor antagonist, did not prove effective in preventing chronic cluster headaches (CCH) in a clinical trial. Further research is needed to understand CGRP

More Related Videos

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

681

Related Experiment Videos

Last Updated: Sep 19, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.3K
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

681

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Calcitonin gene-related peptide (CGRP) plays a role in cluster headache (CH) pathophysiology.
  • Limited prophylactic treatment options exist for chronic cluster headache (CCH).

Purpose of the Study:

  • To evaluate if erenumab, a CGRP receptor antagonist, is superior to placebo for CCH prophylaxis.

Main Methods:

  • A 12-week, double-blind, placebo-controlled randomized clinical trial (CHERUB01) involving 81 participants with CCH.
  • Participants received either erenumab (loading dose 280 mg, then 140 mg) or placebo subcutaneously.
  • Primary endpoint: reduction in mean weekly CH attacks over weeks 5 and 6.

Main Results:

  • Erenumab did not significantly reduce weekly CH attacks compared to placebo (mean reduction -7.3 vs -5.9 attacks).
  • No significant difference in 50% responder rates or Patient Global Impression of Improvement (PGI-I) scores between groups.
  • Adverse events were more frequent with erenumab (65.9%) than placebo (42.5%), mostly mild to moderate.

Conclusions:

  • CGRP receptor blockade with erenumab was not effective for CCH prophylaxis in this trial.
  • The study suggests further investigation into CGRP's role in CCH is warranted.